Traders bought shares of Merck & Company, Inc. (NYSE:MRK) on weakness during trading on Tuesday. $147.76 million flowed into the stock on the tick-up and $92.56 million flowed out of the stock on the tick-down, for a money net flow of $55.20 million into the stock. Of all equities tracked, Merck & had the 12th highest net in-flow for the day. Merck & traded down ($0.11) for the day and closed at $54.99
A number of research analysts recently issued reports on the company. upgraded Merck & from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 9th. BidaskClub lowered Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. UBS AG reduced their price objective on Merck & from $72.00 to $67.00 and set a “buy” rating for the company in a research report on Monday, October 30th. Barclays PLC downgraded Merck & from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $72.00 to $62.00 in a research note on Monday, October 30th. Finally, Cowen and Company reaffirmed a “hold” rating and set a $70.00 target price on shares of Merck & in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. Merck & presently has a consensus rating of “Hold” and an average target price of $67.07.
The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $151,151.77, a P/E ratio of 14.26, a P/E/G ratio of 2.39 and a beta of 0.78.
In other news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.25% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in MRK. Janus Henderson Group PLC raised its position in shares of Merck & by 172.3% during the third quarter. Janus Henderson Group PLC now owns 6,705,564 shares of the company’s stock worth $429,347,000 after purchasing an additional 4,243,246 shares during the period. Capital International Investors raised its position in shares of Merck & by 55.3% during the third quarter. Capital International Investors now owns 9,623,382 shares of the company’s stock worth $616,185,000 after purchasing an additional 3,428,400 shares during the period. Vanguard Group Inc. raised its position in shares of Merck & by 1.7% during the second quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock worth $12,442,709,000 after purchasing an additional 3,312,459 shares during the period. Stifel Financial Corp raised its position in shares of Merck & by 95,700.4% during the third quarter. Stifel Financial Corp now owns 3,281,163 shares of the company’s stock worth $210,016,000 after purchasing an additional 3,277,738 shares during the period. Finally, Amundi Pioneer Asset Management Inc. raised its position in shares of Merck & by 415.5% during the third quarter. Amundi Pioneer Asset Management Inc. now owns 3,560,465 shares of the company’s stock worth $227,977,000 after purchasing an additional 2,869,844 shares during the period. 73.15% of the stock is currently owned by institutional investors.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.